Advanced searches left 3/3

Dolutegravir - DOAJ

Summarized by Plex Scholar
Last Updated: 22 June 2022

* If you want to update the article please login/register

A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy

In a clinical trial in Uganda and South Africa, we compared HRQoL among treatment-nau00efve pregnant women randomly randomized to dolutegravir- or efavirenz-based ART. The primary research findings were physical fitness summary and mental health summary scores, with the 11 MOS-HIV subscales being secondary findings. PHS numbers in the dolutegravir-based arm were higher, while MHS gains in the efavirenz-based armat 24 and 48 weeks were higher in the efavirenz-based arm. An increase in MHS scores was found in the multivariate study, where owning a bank account, using the internet, and longer treatment duration were all linked to rises in MHS ratings. Conclusion In late pregnancy, we discovered no significant differences in HRQoL outcomes among HIV-positive women, from dolutegravir relative to efavirenz. In the first year after delivery, hikes in HRQoL in the first year have occurred, suggesting more resources for the introduction of ART in HIV-positive women who are late in pregnancy.

Source link: https://doi.org/10.1186/s12981-022-00446-3


Inhibition of Adipose Tissue Beiging by HIV Integrase Inhibitors, Dolutegravir and Bictegravir, Is Associated with Adipocyte Hypertrophy, Hypoxia, Elevated Fibrosis, and Insulin Resistance in Simian Adipose Tissue and Human Adipocytes

Adipose tissue growth is promoted by adipose tissue gain for people with HIV. The emergence of beige adipocytes in white AT could play a significant role in limiting excess lipid storage and associated adipocyte dysfunction by increasing energy consumption and underlying adipocyte dysfunction. Beige differentiation in ASCs was impeded by reduced expression of beige markers and lower cell respiration, as shown by lower expression of beige markers and reduced cell respiration. Our results show that adipocyte hypertrophy induced by INSTIs is triggered by hypoxia in fat fibrosis, beiging inhibition, and, inevitably, more hypertrophy and increased insulin resistance.

Source link: https://doi.org/10.3390/cells11111841


Isotopic Radiolabeling of the Antiretroviral Drug [ 18 F]Dolutegravir for Pharmacokinetic PET Imaging

Deciphering the drug/virus/host interactions at infected cell reservoirs is a key contributor to HIV-1 remission in which positron emission tomography imaging using radiolabeled antiretroviral drugs is a valuable asset. Dolutegravir is one of the most commonly used therapeutic drugs to treat HIV, and can be isotopically labeled with fluorine-18. In 90 percent conversion followed by nitrile reduction using sodium borohydride and aqueous nickel chloride with 72% conversion. In 5. 1 u00b1 0. 8% decay-corrected radiochemical yield within 95 min, final peptide coupling reaction was followed by HPLC purification and formulation yielded by a ready-to-inject [18 F]DTG in 5. 1 F]cle coupling reaction, followed by HPLC purification and formulation of a ready-to-inject [18 F]DTG in 5. 1 u00b1 0. 8% decay-corrected radiochemical yield within 5. 1 [18 F]DTG was suitable for in vivo injections with > 99% chemical and radiochemical purity and a molar activity of 83 GBQ/mol, according to analytical HPLC.

Source link: https://doi.org/10.3390/ph15050587


Could a Dolutegravir-Based Antiretroviral Therapy Lead to Clinical Obesity? A Retrospective Cohort Study Conducted at Hawassa University Comprehensive Specialized Hospital in Hawassa, Sidama, Ethiopia

We looked at weight gain differences among human immunodeficiency syndrome/acquired immunodeficiency syndrome patients on antiretroviral therapy who have been switched to tenofovir/lamivudine/efavirenz-based therapy versus those who are not maintained on a tenofovir/lamivudine/efavirenz-based regimen in this review. Patients with optimal viral suppression at Hawassa University Comprehensive Specialized Hospital's antiretroviral clinic at Hawassa University Comprehensive Hospital were studied by a facilities-based retrospective observational cohort study in the hopes of weight change differences between tenofovir/lamivudine/dolutegravir and tenofovir/lamivudine/dolutegravir and tenofovir/lamivudine/lamivudine/e at enrolled at Hawas at Hawassa University Comprehensive Specialized Hospital's a University Comprehensive Specialized Hospital's. The majority of patients were on a tenofovir/lamivudine/efavirenz-based diet, with 211 of whom were switched from tenofovir/efavirenz to tenofovir/lamivudine/dolutegravir, and the rest were on a tenofovir/lamivudine/efavirenz-based regimen. According to this report, tenofovir/lamivudine/dolutegravir-based antiretroviral medication users are more likely to gain weight, and physicians should warn them of the risks of weight gain as well as cost-effective ways to avoid weight gain in these patients due to poor health outcomes.

Source link: https://doi.org/10.1155/2022/2965325

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions